Cargando…

Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors

The two most commonly used immunohistochemical markers for neuroendocrine cells and their tumors are chromogranin A (CgA) and synaptophysin (SPY). CgA is a marker for neuroendocrine secretory granules of four pancreatic hormones and gastrin while SPY is a marker for synaptic vesicles in neuroendocri...

Descripción completa

Detalles Bibliográficos
Autor principal: Tomita, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416176/
https://www.ncbi.nlm.nih.gov/pubmed/32020844
http://dx.doi.org/10.17305/bjbms.2020.4632
_version_ 1783569277738024960
author Tomita, Tatsuo
author_facet Tomita, Tatsuo
author_sort Tomita, Tatsuo
collection PubMed
description The two most commonly used immunohistochemical markers for neuroendocrine cells and their tumors are chromogranin A (CgA) and synaptophysin (SPY). CgA is a marker for neuroendocrine secretory granules of four pancreatic hormones and gastrin while SPY is a marker for synaptic vesicles in neuroendocrine cells, which release classic neurotransmitters such as acetylcholine and others. CgA is involved in synthesis and secretion of peptide hormones through exocytosis while the function of SPY is elusive. Thirty-five pancreatic neuroendocrine tumors (Pan-NETs) were studied, consisting of 14 insulinomas, 8 gastrinomas, 2 glucagonomas, 6 pancreatic polypeptidomas and 5 non-functioning tumors, and were immunostained for four pancreatic hormones, gastrin, CgA, and SPY. Majority of Pan-NETs were less immunostained for the endocrine hormones and CgA than the normal pancreatic endocrine cells. CgA immunostaining mostly correlates with each hormone staining in non-β-cell tumors, while SPY immunostaining recognizes endocrine cells diffusely in the cytoplasm. CgA immunostaining is less in insulinomas than in non-β-cell tumors, and CgA immunostaining may distinguish CgA-weaker insulinomas from CgA-stronger non-β-cell tumors. CgA immunostaining may be used as an independent marker for biological aggressiveness in non-β-cell Pan-NETs. The serum CgA levels are higher in subjects harboring non-β-cell tumors than those harboring insulinomas, and the serum CgA elevates in parallel to the increasing metastatic tumor mass. Thus, CgA positive immunostaining in Pan-NETs correlates with the elevated serum levels of CgA for diagnosing CgA-positive non-β-cell Pan-NETs and the increasing serum CgA levels indicate increasing metastatic tumor mass.
format Online
Article
Text
id pubmed-7416176
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-74161762020-08-13 Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors Tomita, Tatsuo Bosn J Basic Med Sci Research Article The two most commonly used immunohistochemical markers for neuroendocrine cells and their tumors are chromogranin A (CgA) and synaptophysin (SPY). CgA is a marker for neuroendocrine secretory granules of four pancreatic hormones and gastrin while SPY is a marker for synaptic vesicles in neuroendocrine cells, which release classic neurotransmitters such as acetylcholine and others. CgA is involved in synthesis and secretion of peptide hormones through exocytosis while the function of SPY is elusive. Thirty-five pancreatic neuroendocrine tumors (Pan-NETs) were studied, consisting of 14 insulinomas, 8 gastrinomas, 2 glucagonomas, 6 pancreatic polypeptidomas and 5 non-functioning tumors, and were immunostained for four pancreatic hormones, gastrin, CgA, and SPY. Majority of Pan-NETs were less immunostained for the endocrine hormones and CgA than the normal pancreatic endocrine cells. CgA immunostaining mostly correlates with each hormone staining in non-β-cell tumors, while SPY immunostaining recognizes endocrine cells diffusely in the cytoplasm. CgA immunostaining is less in insulinomas than in non-β-cell tumors, and CgA immunostaining may distinguish CgA-weaker insulinomas from CgA-stronger non-β-cell tumors. CgA immunostaining may be used as an independent marker for biological aggressiveness in non-β-cell Pan-NETs. The serum CgA levels are higher in subjects harboring non-β-cell tumors than those harboring insulinomas, and the serum CgA elevates in parallel to the increasing metastatic tumor mass. Thus, CgA positive immunostaining in Pan-NETs correlates with the elevated serum levels of CgA for diagnosing CgA-positive non-β-cell Pan-NETs and the increasing serum CgA levels indicate increasing metastatic tumor mass. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2020-08 /pmc/articles/PMC7416176/ /pubmed/32020844 http://dx.doi.org/10.17305/bjbms.2020.4632 Text en Copyright: © The Author(s) (2020) http://creativecommons.org/licenses/by/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Research Article
Tomita, Tatsuo
Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title_full Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title_fullStr Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title_full_unstemmed Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title_short Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
title_sort significance of chromogranin a and synaptophysin in pancreatic neuroendocrine tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416176/
https://www.ncbi.nlm.nih.gov/pubmed/32020844
http://dx.doi.org/10.17305/bjbms.2020.4632
work_keys_str_mv AT tomitatatsuo significanceofchromograninaandsynaptophysininpancreaticneuroendocrinetumors